Literature DB >> 32790119

Clinical characterization and hematopoietic stem cell transplant outcomes for congenital sideroblastic anemia caused by a novel pathogenic variant in SLC25A38.

Kelsey Uminski1, Donald S Houston2, Jessica N Hartley3, Jing Liu3, Geoffrey D E Cuvelier4, Sara J Israels4.   

Abstract

BACKGROUND: Congenital sideroblastic anemia (CSA) constitutes an uncommon category of inherited anemia often associated with pathologic iron accumulation. Pathogenic variants in several genes have been identified as causative for CSA. Autosomal recessive pathogenic variants in the mitochondrial glycine transporter SLC25A38 have been implicated in a subset of patients with CSA. PROCEDURE: We describe seven individuals of Canadian Cree descent with a known or inferred homozygous novel founder missense variant in SLC25A38 (c.560G>A, p.Arg187Gln).
RESULTS: All individuals presented as young children (median age 6 months) with severe microcytic, hypochromic anemia associated with pretransfusion iron overload, requiring red cell transfusion support and iron chelation. Six individuals received pyridoxine supplementation; two demonstrating transient partial responses. Three individuals underwent allogeneic hematopoietic stem cell transplantation (HSCT). One individual with significant iron loading died in the posttransplant period due to complications of sepsis. The other two individuals remain transfusion-free following HSCT.
CONCLUSIONS: Despite a common genetic etiology, phenotypic variability was noted in this cohort. A transient response to pyridoxine was noted in two individuals but should not be considered a long-term therapeutic strategy. HSCT was curative when performed before significant iron loading occurred. Early identification of CSA and timely HSCT can result in excellent long-term outcomes.
© 2020 Wiley Periodicals LLC.

Entities:  

Keywords:  SLC25A38; inherited anemia; sideroblastic anemia

Year:  2020        PMID: 32790119     DOI: 10.1002/pbc.28623

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  3 in total

1.  Inhibition of BTK and PI3Kδ impairs the development of human JMML stem and progenitor cells.

Authors:  Baskar Ramdas; Lisa Deng Yuen; Lakshmi Reddy Palam; Roshini Patel; Santhosh Kumar Pasupuleti; Victoria Jideonwo; Ji Zhang; Callista Maguire; Eric Wong; Rahul Kanumuri; Chujing Zhang; George Sandusky; Rebecca J Chan; Chi Zhang; Elliot Stieglitz; Laura Haneline; Reuben Kapur
Journal:  Mol Ther       Date:  2022-04-20       Impact factor: 12.910

2.  SLC25A38 as a novel biomarker for metastasis and clinical outcome in uveal melanoma.

Authors:  Zhongyi Fan; Jingjing Duan; Pu Luo; Ling Shao; Qiong Chen; Xiaohua Tan; Lei Zhang; Xiaojie Xu
Journal:  Cell Death Dis       Date:  2022-04-11       Impact factor: 8.469

Review 3.  SLC25A38 congenital sideroblastic anemia: Phenotypes and genotypes of 31 individuals from 24 families, including 11 novel mutations, and a review of the literature.

Authors:  Matthew M Heeney; Simon Berhe; Dean R Campagna; Joseph H Oved; Peter Kurre; Peter J Shaw; Juliana Teo; Mayada A Shanap; Hoda M Hassab; Bertil E Glader; Sanjay Shah; Ayami Yoshimi; Afshin Ameri; Joseph H Antin; Jeanne Boudreaux; Michael Briones; Kathryn E Dickerson; Conrad V Fernandez; Roula Farah; Henrik Hasle; Sioban B Keel; Timothy S Olson; Jacquelyn M Powers; Melissa J Rose; Akiko Shimamura; Sylvia S Bottomley; Mark D Fleming
Journal:  Hum Mutat       Date:  2021-08-05       Impact factor: 4.878

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.